Firstv Biotechnology Co vaccine achieves national recognition

In February this year, Guizhou Firstv Biotechnology Co, located in Guiyang High-tech Industrial Development Zone, received a National New Veterinary Drug Certificate for its first self-developed product, the Trivalent Inactivated Vaccine, which targets Newcastle Disease, Avian Influenza, and Avian Adenovirus.

This milestone signifies national-level recognition of Firstv Biotechnology's innovative research and development capabilities.

"The Trivalent Inactivated Vaccine protects against three diseases with a single shot, significantly reducing the number of vaccinations needed and improving immunization efficiency," said Xu Juncai, chairman of Firstv.

Since its market launch in July, the first batch of over 8,000 vaccine bottles has been sold to regions such as Guangdong, Henan, and Shandong provinces.

"Vaccine development is costly, time-consuming, and faces low success rates. For example, it took us from 2015 until now to develop the Trivalent Inactivated Vaccine," Xu explained.

Luo Yi, director of the company's R&D department, said that on Sept 5, the company exported 6,000 bottles of another Trivalent Inactivated Vaccine, which prevents Newcastle Disease, Infectious Bronchitis, and Avian Influenza (H9 subtype), to Vietnam.

Xu also noted, "In the future, while expanding our presence in the domestic market, we will also target markets in the Arab region, West Asia, ASEAN, and South America."

The company boasts over 10 products under development, 21 patents, four clinical veterinary drug approvals, and four national new veterinary drug certificates. Additionally, nine of its technological achievements have already been commercialized.